Venaxis changes name to Bioptix, symbol to BIOP

Venaxis changes name to Bioptix, symbol to BIOP

BOULDER --Venaxis Inc. (Nasdaq: APPY), announced it is changing the companys name to Bioptix Inc . following approval from shareholders at the 2016 annual meeting of shareholders. The... Read More

Monday December 12, 2016 0 comments Tags: Boulder, Venaxis, BiOptix, Steve Lundy, APPY, BIOP

Venaxis announces acquisition of BiOptix

Venaxis announces acquisition of BiOptix

CASTLE ROCK -- Venaxis Inc. (Nasdaq: APPY), today announced it has acquired Boulder-based BiOptix Diagnostics, Inc. ("BiOptix"), a privately held company. Venaxis has developed a proprietary... Read More

Wednesday September 14, 2016 0 comments Tags: Venaxis, Castle Rock, Boulder, BiOptix, Surface Plasmon Resonance, Steve Lundy

Venaxis selling 8,335,000 common stock shares to raise $18.4M to advance APPY1 Test in U.S.

Venaxis selling 8,335,000 common stock shares to raise $18.4M to advance APPY1 Test in U.S.

CASTLE ROCK - Venaxis Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE-Marked Appy1 Test, announced a $2.40-per-share pricing... Read More

By: InnovatioNews Friday April 4, 2014 0 comments Tags: APPY1, Castle Rock, FDA, Venaxis

Venaxis closes public stock offering, raises $14.4 million for APPY1

Venaxis closes public stock offering, raises $14.4 million for APPY1

CASTLE ROCK - Venaxis Inc. (Nasdaq: APPY) announced it has closed its underwritten public offering that resulted in the sale of 11.5 million shares of common stock and gross proceeds of $14.4... Read More

By: Steve Friday May 31, 2013 0 comments Tags: APPY1, Castle Rock, Steve Lundy, Venaxis

Venaxis expands European distribution network for APPY1 appendicitis test

Venaxis expands European distribution network for APPY1 appendicitis test

CASTLE ROCK - Venaxis Inc . (Nasdaq: APPY), an in vitro diagnostic company focused on gaining FDA approval and commercialization of its APPY1 appendicitis test, announced it has signed... Read More

By: Steve Tuesday March 19, 2013 0 comments Tags: APPY1, Castle Rock, Don Hurd, EMELCA Bioscience, Venaxis

Venaxis signs agreement with European distributor, gets first APPY1 order

Venaxis signs agreement with European distributor, gets first APPY1 order

CASTLE ROCK - Venaxis Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA approval for its blood-based appendicitis test, announced it has signed its first European... Read More

By: Steve Thursday February 14, 2013 0 comments Tags: APPY1, Castle Rock, Don Hurd, EMELCA Bioscience, Venaxis

Venaxis obtains CE Mark for APPY1 appendicitis test

CASTLE ROCK - Venaxis Inc. (Nasdaq: APPY), an in-vitro diagnostic company, has fulfilled the requirements for CE Marking in Europe for its APPY1 blood-based appendicitis test, the company announced.... Read More

By: Steve Tuesday January 8, 2013 0 comments Tags: APPY1, Castle Rock, CE Mark, Steve Lundy, Venaxis

Venaxis files for CE Mark approval for European commercialization

Venaxis files for CE Mark approval for European commercialization

CASTLE ROCK - Venaxis Inc. (Nasdaq: APPY) has filed for CE Mark approval in Europe for APPY 1, its blood-based appendicitis test, the company announced. Venaxis said it expects to obtain CE... Read More

By: Steve Wednesday December 26, 2012 0 comments Tags: appendicitis, APPY 1, Castle Rock, CE Mark, Don Hurd, Venaxis